Search This Blog

Monday, August 17, 2026

argenx reports positive Phase 3 ALKIVIA topline data for VYVGART Hytrulo in autoimmune myositis

 

argenx reports positive Phase 3 ALKIVIA topline data for VYVGART Hytrulo in autoimmune myositis, including first successful Phase 3 result in IMNM

  • Detailed topline data showed VYVGART Hytrulo met the primary endpoint with statistically significant improvements in autoimmune myositis in ALKIVIA.
  • The ALKIVIA study reported a favorable safety profile for VYVGART Hytrulo in autoimmune myositis, according to argenx.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)